Ozempic entered the public conversation as a diabetes drug, then became famous as a weight loss drug. Neither label fully describes what this class of medication has turned into. Across a series of approvals and trial results, GLP-1 drugs have expanded into treatments for kidney disease, heart failure, obstructive sleep apnea, and advanced liver disease, with researchers now studying their effects on conditions as different as alcohol use disorder and certain cancers. What started as a way to manage blood sugar has become one of the broadest reaching drug classes in modern chronic disease care.
What Conditions Are GLP-1 Drugs Now Approved to Treat?
As of 2026, the class as a whole covers six distinct approved uses: type 2 diabetes, obesity and being overweight, established cardiovascular disease, chronic kidney disease, a form of advanced liver disease called MASH, and obstructive sleep apnea. Not every drug in the class is approved for every one of those conditions individually, since each specific medication has gone through its own trials and its own regulatory review, but the category overall has moved well beyond its original purpose.
How Is a Diabetes Drug Treating Kidney Disease and Heart Failure?
The kidney approval came from a large trial that followed more than 3,500 people who had both type 2 diabetes and chronic kidney disease. Patients taking semaglutide, the active ingredient in Ozempic and Wegovy, saw a meaningfully lower risk of their kidney disease progressing, along with a 24 percent reduction in the combined risk of kidney failure and cardiovascular death. That result was strong enough for the drug to become the first GLP-1 medication approved specifically to slow the progression of kidney disease.
The heart failure data is similarly striking. In a form of heart failure called heart failure with preserved ejection fraction, where the heart’s chambers do not relax and fill with blood properly, GLP-1 treatment has been associated with roughly a 40 percent relative reduction in risk compared to older therapies. A separate large trial found a 20 percent reduction in major cardiovascular events, including heart attack and stroke, among overweight or obese patients with existing cardiovascular disease who did not have diabetes, suggesting the cardiovascular benefit is not limited to people managing blood sugar.
What Is Happening With Sleep Apnea Specifically?
Obstructive sleep apnea became an approved indication after trial results showed a substantial reduction in how often breathing was interrupted during sleep, measured through a standard rate of pauses per hour. Notably, roughly half the patients in these trials saw improvement significant enough to be considered clinical remission, meaning symptoms resolved to the point that continuous airway pressure therapy, the standard treatment for sleep apnea, was no longer needed for many of them. Given how disruptive and difficult to treat sleep apnea can be, this has become one of the more closely watched expansions in the entire GLP-1 story.
What About Liver Disease?
Metabolic dysfunction associated steatohepatitis, generally known as MASH, is an advanced and inflammatory form of fatty liver disease that can progress to scarring, or fibrosis, and eventually liver failure if untreated. Trial data on higher dose semaglutide has shown the potential to actually resolve liver fibrosis in some patients, not just slow its progression, which is a meaningfully different outcome than most existing liver disease treatments have been able to offer.
What Other Conditions Are Being Studied, and How Solid Is That Evidence?
This is where the research gets more speculative, and it is worth being honest about the difference between an approved use and an early signal. Clinical trials have shown GLP-1 drugs can reduce alcohol consumption in people with alcohol use disorder, likely by altering activity in the brain’s reward pathways. Early research has also found associations between GLP-1 use and lower cancer risk, including one large study that found a 17 percent reduction in overall cancer risk across more than 86,000 people, with more specific research pointing to a possible 30 percent lower risk of breast cancer among users.
Trials looking at Alzheimer’s and Parkinson’s disease, by contrast, have produced mixed results so far, partly because these drugs have a harder time crossing into the brain in meaningful concentrations. That gap between promising early data and a confirmed, approved use is exactly why doctors are cautious about treating every emerging headline as settled science.
What Should You Know About the Tradeoffs?
The expanding benefits do not erase the tradeoffs that come with this class of drugs. Rapid weight loss on GLP-1 medications can include a meaningful loss of lean muscle mass, with some research putting the range as high as 15 to 25 percent of total weight lost. Deficiencies in vitamin B12, vitamin D, and magnesium have also been flagged as something to monitor during treatment, particularly as appetite and food intake drop. None of this means the drugs are unsafe for their approved uses, but it does mean they work best as part of a coordinated care plan that accounts for nutrition, not as a standalone prescription.
Is This the Same Drug for Every Condition?
Not exactly. The GLP-1 class now includes multiple different molecules and formulations, including dual acting drugs like tirzepatide that target two hormone pathways instead of one, and newer triple acting drugs like retatrutide currently in trials, which have shown weight loss results approaching 29 percent in early data. These are not interchangeable products with different brand names attached. Each has its own approved uses, its own dosing, and its own safety profile, which is part of why a prescription tailored to your specific condition matters more than picking based on which version is most talked about.
What Should You Ask Your Doctor?
If you are managing a chronic condition and wondering whether this class of drugs is relevant to you, a few questions are worth raising directly:
- Is there a GLP-1 medication specifically approved for my condition, not just weight loss in general?
- How will we monitor muscle mass and key nutrient levels if I start treatment?
- Which specific drug in this class fits my situation, and why that one over another?
- What would we expect to see, and by when, to know if it is working for my specific condition?
The Bottom Line
GLP-1 drugs started as a tool for managing blood sugar and ended up reshaping how medicine approaches an entire cluster of chronic conditions that used to be treated separately. Kidney disease, heart failure, sleep apnea, and liver disease do not typically share a treatment plan, and yet increasingly, they share one now. The story is not finished, and some of the most exciting possibilities are still unproven, but the shift from a single purpose drug to a genuine chronic disease platform has already happened.
This article provides general health information and is not a substitute for personalized medical advice. Whether a GLP-1 medication is appropriate for you depends on your specific diagnosis, health history, and other medications, so talk to your doctor before starting or stopping any treatment.
